Africa Clinical Trials Market Size, Share & Industry Analysis, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Application (Oncology, CNS Disorder, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 7.2% from 2024-2032

Unit

Value (USD billion)

Segmentation

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Application

• Oncology
• CNS Disorder
• Cardiology
• Infectious Disease
• Metabolic Disorder
• Renal/Nephrology
• Others

By Region

• West Africa (by Phase, by Application, and by Country/Sub-region)
• Senegal (by Phase and by Application)
• Mali (by Phase and by Application)
• Burkina Faso (by Phase and by Application)
• Cote d’Ivoire (by Phase and by Application)
• Ghana (by Phase and by Application)
• Gambia (by Phase and by Application)
• Nigeria (by Phase and by Application)
• Rest of West Africa (by Phase and by Application)
• Central Africa (by Phase, by Application, and by Country/Sub-region)
• Cameroon (by Phase and by Application)
• Congo & DRC (by Phase and by Application)
• Gabon (by Phase and by Application)
• Republic of Central Africa (by Phase and by Application)
• Rest of Central Africa (by Phase and by Application)
• East Africa (by Phase, by Application, and by Country/Sub-region)
• Kenya (by Phase and by Application)
• Uganda (by Phase and by Application)
• Tanzania (by Phase and by Application)
• Rest of East Africa (by Phase and by Application)
• South Africa (by Phase, by Application, and by Country/Sub-region)
• Angola (by Phase and by Application)
• South Africa (by Phase and by Application)
• Mozambique (by Phase and by Application)
• Rest of South Africa (by Phase and by Application)